Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
The production of recombinant human granulocyte colony stimulating factor (HuG-CSF) by gene cloning has made this growth factor available in large quantities for clinical application. There is accumulating evidence to suggest that the glycosylation of HuG-CSF confers advantages in terms of in vitro stability to temperature, pH and degradation by proteases, and a recent report attributes a greater biological potency, in the absence of larger biological mass, to the property of glycosylation. In this study, the biological potency of glycosylated rHuG-CSF (lenograstim) was compared with that of non-glycosylated rmetHuG-CSF (filgrastim) and a non-glycosylated rHuG-CSF (non-commercial preparation), using duplicate assays of neutrophil and erythroid colony formation in three human bone marrows. Serial doubling dilutions of each rHuG-CSF resulted in a concentration range of 0.008-128 ng/ml. Qualitative (number) and quantitative (size) assessments of colonies were performed at day 14 of culture. Lenograstim proved twice as potent as filgrastim (and non-commercial rHuG-CSF) at maximal colony stimulation, and 20 times more potent than both at half-maximal colony stimulation (P = 0.0001). Incubation with lenograstim also produced a higher proportion of colonies with > 200 cells than either of the other preparations. In conclusion, glycosylated rHuG-CSF (lenograstim) had a greater qualitative and quantitative potency than the non-glycosylated rHuG-CSFs (filgrastim and non-commercial rHuG-CSF), indicating that glycosylation confers a potency advantage on lenograstim.
Nissen
C
C
Department of Research, University Hospital, Basel, Switzerland.
D003114:Colony-Forming Units Assay; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D015672:Erythroid Precursor Cells / Q000187:drug effects*; D000069585:Filgrastim; D006031:Glycosylation; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D000078224:Lenograstim; D009504:Neutrophils / Q000187:drug effects*; D011994:Recombinant Proteins / Q000494:pharmacology
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim